RFA
RXRX icon

Resurgent Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Resurgent Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136K Buy
44,200
+23,900
+118% +$92.4K 0.05% 244
2025
Q4 		$83K Buy
+20,300
New +$101K 0.04% 211

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Resurgent Financial Advisors's RXRX Position: Q1 2026 in Review

Resurgent Financial Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 118% in Q1 2026, buying an estimated $92.4K and bringing the position to 44,200 shares worth $136K. The position accounts for 0.05% of the portfolio, ranked #244.

Resurgent Financial Advisors first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Resurgent Financial Advisors held 44,200 shares of Recursion Pharmaceuticals worth $136K as of Q1 2026.
  • Resurgent Financial Advisors bought 23,900 Recursion Pharmaceuticals shares in Q1 2026, an estimated $92.4K.
  • Recursion Pharmaceuticals made up 0.05% of Resurgent Financial Advisors's portfolio in Q1 2026, its #244 holding.
  • Resurgent Financial Advisors first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Resurgent Financial Advisors's 13F filing for Q1 2026, filed 13 May 2026.